MYCN and neuroblastoma: ALK combined with N-myc (ALK F1174 C/N-myc) co-activates Wnt/β-catenin signaling, and Wnt inhibitors targeting these entities can inhibit the growth and metastasis of neuroendocrine prostate cancer and neuroblastoma [51].